ALX Oncology Holdings logo
ALX Oncology Holdings ALXO
$ 1.98 0.25%

Annual report 2025
added 03-09-2026

report update icon

ALX Oncology Holdings Net Debt 2011-2026 | ALXO

Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]

Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.

Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.

Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.

Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.

Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.

Annual Net Debt ALX Oncology Holdings

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
-10.9 M -7.66 M -11.9 M -38.7 M - - -3.6 M -8.26 M - - - - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
-3.6 M -38.7 M -13.5 M

References

  1. Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.

Net Debt of other stocks in the Biotechnology industry

Issuer Net Debt Price % 24h Market Cap Country
ADC Therapeutics SA ADC Therapeutics SA
ADCT
-459 M $ 3.78 - $ 105 M schweizSchweiz
MorphoSys AG MorphoSys AG
MOR
163 M - 2.43 % $ 254 M germanyGermany
Akebia Therapeutics Akebia Therapeutics
AKBA
-133 M $ 1.35 -2.17 % $ 347 M usaUSA
Akari Therapeutics, Plc Akari Therapeutics, Plc
AKTX
-5.45 M $ 3.5 -21.7 % $ 236 B britainBritain
Aldeyra Therapeutics Aldeyra Therapeutics
ALDX
-129 M $ 1.58 -4.82 % $ 94.9 M usaUSA
Aligos Therapeutics Aligos Therapeutics
ALGS
-132 M $ 8.36 4.89 % $ 82.6 M usaUSA
Alnylam Pharmaceuticals Alnylam Pharmaceuticals
ALNY
-604 M $ 330.71 3.72 % $ 43.3 B usaUSA
Altimmune Altimmune
ALT
-9.22 M $ 3.47 3.89 % $ 306 M usaUSA
Amgen Amgen
AMGN
41 B $ 346.45 -0.43 % $ 186 B usaUSA
I-Mab I-Mab
IMAB
-1.06 B - - $ 866 M chinaChina
Amneal Pharmaceuticals Amneal Pharmaceuticals
AMRX
2.29 B $ 12.37 -0.92 % $ 3.88 B usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
-402 M - - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
2.27 M - 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
-4.01 M - -13.47 % $ 169 M franceFrance
Anika Therapeutics Anika Therapeutics
ANIK
-46 M $ 15.0 1.32 % $ 220 M usaUSA
ANI Pharmaceuticals ANI Pharmaceuticals
ANIP
166 M $ 76.34 2.87 % $ 1.47 B usaUSA
Annexon Annexon
ANNX
-136 M $ 5.64 2.45 % $ 875 M usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
-2.77 M $ 0.92 -1.11 % $ 5.02 M chinaChina
Midatech Pharma plc Midatech Pharma plc
MTP
-6.17 M - -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
-824 K - -1.52 % $ 24.7 M usaUSA
Aprea Therapeutics Aprea Therapeutics
APRE
-130 M $ 0.73 2.63 % $ 4.77 M usaUSA
Aquestive Therapeutics Aquestive Therapeutics
AQST
-75.5 M $ 4.15 0.48 % $ 444 M usaUSA
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
-206 M $ 8.43 4.98 % $ 231 M israelIsrael
Ardelyx Ardelyx
ARDX
136 M $ 6.08 2.27 % $ 1.47 B usaUSA
argenx SE argenx SE
ARGX
-89.9 M $ 752.05 0.75 % $ 25 B niderlandNiderland
Acorda Therapeutics Acorda Therapeutics
ACOR
114 M - -24.86 % $ 820 K usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
65.3 M $ 23.93 1.27 % $ 3.04 B usaUSA
Arvinas Arvinas
ARVN
-141 M $ 11.11 2.4 % $ 788 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
31.1 M - - $ 86.2 M usaUSA
Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals
ARWR
-115 M $ 61.57 0.88 % $ 8.24 B usaUSA
Advaxis Advaxis
ADXS
3.42 M - -9.65 % $ 45.9 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
-56.5 M - - $ 10.1 M usaUSA
Assembly Biosciences Assembly Biosciences
ASMB
-55.8 M $ 30.01 3.43 % $ 336 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
-65.1 M - 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
12.6 M - -10.17 % $ 12.2 K usaUSA
AIkido Pharma AIkido Pharma
AIKI
-31.2 M - 1.93 % $ 17.4 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
-30.2 M - - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
-36 M - - $ 26.5 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
-340 M - - $ 3.67 B usaUSA
Akouos Akouos
AKUS
-92.9 M - 0.23 % $ 488 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
246 M - - - russiaRussia
Actinium Pharmaceuticals Actinium Pharmaceuticals
ATNM
-46.3 M $ 1.14 16.28 % $ 35.6 M usaUSA
Atossa Therapeutics Atossa Therapeutics
ATOS
-39.6 M $ 5.21 -2.89 % $ 44.9 M usaUSA
Atara Biotherapeutics Atara Biotherapeutics
ATRA
1.89 M $ 5.03 0.7 % $ 63.1 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
-29.5 M - 3.16 % $ 1.9 M usaUSA
Aurinia Pharmaceuticals Aurinia Pharmaceuticals
AUPH
-26.8 M $ 16.04 2.75 % $ 2.16 B canadaCanada
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
-32.7 M $ 1.42 0.35 % $ 378 M britainBritain
Alpine Immune Sciences Alpine Immune Sciences
ALPN
-63.9 M - - $ 2.17 B usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
-3.44 M - 10.36 % $ 9.8 M usaUSA